| Literature DB >> 35392952 |
Yuhan Yang1, Yin Zhou1, Chen Zhou1, Xuelei Ma2.
Abstract
BACKGROUND: Deep learning methods have great potential to predict tumor characterization, such as histological diagnosis and genetic aberration. The objective of this study was to evaluate and validate the predictive performance of multimodality imaging-derived models using computer-aided diagnostic (CAD) methods for prediction of MDM2 gene amplification to identify well-differentiated liposarcoma (WDLPS) and lipoma.Entities:
Keywords: Computed tomography; Convolutional neural network; Deep learning; Lipoma; Magnetic resonance imaging; Multimodality model; Well differentiated liposarcoma
Mesh:
Year: 2022 PMID: 35392952 PMCID: PMC8991509 DOI: 10.1186/s13023-022-02304-x
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Fig. 1A general flowchart of data analysis. A Imaging-derived features were extracted by the deep learning analysis and handcrafted radiomics analysis on multimodality medical images, including CT and MRI, respectively. B Predictive models on both deep learning and handcrafted radiomics features for classification of lipoma and WDLPS were approached by machine learning methods including features selection and model construction. The deep learning-based model with the optimal performance was chosen to generate a deep learning signature. An integrated differentiation model was constructed by the deep learning signature and independent clinical predictors. All differentiation models were evaluated by ROC curves, precision-recall plots, and calibration plots in both training and validation cohorts. CT, Computed tomography; MRI, Magnetic resonance imaging; WDLPS, Well-differentiated liposarcoma; ROC, Receiver operating characteristic; SVM, Support vector machine
Demographic characteristics of patients in the training and testing cohorts
| Characteristic | All subjects N = 127) | Training cohort (N = 89) | Validation cohort (N = 38) | |
|---|---|---|---|---|
| 0.303 | ||||
| Lipoma | 69 (54.3) | 51 (57.3) | 18 (47.4) | |
| WDLPS | 58 (45.7) | 38 (42.7) | 20 (52.6) | |
| 0.116 | ||||
| Female | 60 (47.2) | 38 (42.7) | 22 (57.9) | |
| Male | 62 (52.8) | 51 (57.3) | 16 (42.1) | |
| 48 (23) | 48 (23) | 49 (19) | 0.904 | |
| ≤ 60, no. (%) | 98 (77.2) | 69 (77.5) | 29 (76.3) | 0.882 |
| > 60, no. (%) | 29 (22.8) | 20 (22.5) | 9 (23.7) | |
| 7.0 (6.4) | 7.0 (6.6) | 7.3 (7.9) | 0.602 | |
| ≤ 10, no. (%) | 85 (66.9) | 59 (66.3) | 26 (68.4) | 0.815 |
| > 10, no. (%) | 42 (33.1) | 30 (33.7) | 12 (31.6) | |
| 0.140 | ||||
| Extremity | 61 (48.0) | 43 (48.3) | 18 (47.4) | |
| Trunk | 41 (32.3) | 25 (28.1) | 16 (42.1) | |
| Abdomen/retroperitoneal | 25 (19.7) | 21 (23.6) | 4 (10.5) | |
| 0.228 | ||||
| Superficial | 15 (11.8) | 13 (14.6) | 2 (5.3) | |
| Deep | 112 (88.2) | 76 (85.4) | 36 (94.7) | |
| 136 (22) | 138 (27) | 134 (17) | 0.383 | |
| Normal, no. (%) | 104 (81.9) | 71 (79.8) | 5 (13.2) | 0.344 |
| Abnormal, no. (%) | 23 (18.1) | 18 (20.2) | 33 (86.8) | |
| 188 (84) | 196 (79) | 185 (100) | 0.992 | |
| Normal (≤ 300), no. (%) | 111 (87.4) | 79 (88.8) | 32 (84.2) | 0.561 |
| Abnormal (> 300), no. (%) | 16 (12.6) | 10 (11.2) | 6 (15.8) | |
| 6.26 (2.53) | 6.05 (2.42) | 6.52 (2.26) | 0.218 | |
| Normal (> 4), no. (%) | 108 (85.0) | 79 (88.8) | 29 (76.3) | 0.101 |
| Abnormal (≤ 4), no. (%) | 19 (15.0) | 10 (11.2) | 9 (23.7) | |
| 42.7 (4.8) | 42.5 (4.6) | 43.7 (5.5) | 0.183 | |
| Normal (> 40), no. (%) | 98 (77.2) | 68 (76.4) | 30 (78.9) | 0.755 |
| Abnormal (≤ 40), no. (%) | 29 (22.8) | 21 (23.6) | 8 (21.1) | |
| 76 (42) | 73 (42) | 80 (48) | 0.517 | |
| Normal (≤ 140), no. (%) | 116 (91.3) | 82 (92.1) | 34 (89.5) | 0.732 |
| Abnormal (> 140), no. (%) | 11 (8.7) | 7 (7.9) | 4 (10.5) | |
| 160 (46) | 155 (38) | 167 (57) | 0.052 | |
| Normal (≤ 220), no. (%) | 110 (86.6) | 80 (89.9) | 30 (78.9) | 0.152 |
| Abnormal (> 220), no. (%) | 17 (13.4) | 9 (10.1) | 8 (21.1) | |
| 10 (10) | 10 (11) | 10 (9) | 0.960 | |
| ≤ 14, no. (%) | 87 (68.5) | 59 (66.3) | 28 (73.7) | 0.412 |
| > 14, no. (%) | 40 (31.5) | 30 (33.7) | 10 (26.3) |
WDLPS, Well-differentiated liposarcoma; IQR, Interquartile range; HGB, Hemoglobin; WBC, White blood cell; ALB, Serum albumin; ALP, Alkaline phosphatase; LDH, Lactate dehydrogenase
aFor male, HGB < 130 is defined abnormal; for female, HGB < 115 is defined abnormal
Predictive performance of significant clinical variables, the deep learning signature, and clinical and clinical-deep learning models in classification of WDLPS and lipoma on patients in the training and validation cohorts
| Parameters | Training cohort | Validation cohort | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC | Accuracy | Sensitivity | Specificity | PPV | NPV | AUC | Accuracy | Sensitivity | Specificity | PPV | NPV | |
| Age | 0.625 (0.505–0.746) | 66.29 (59/89) | 36.84 (22.29–54.00) | 88.24 (75.44–95.13) | 70.00 (45.67–87.16) | 65.22 (52.71–76.02) | 0.514 (0.328–0.700) | 50.00 (19/38) | 25.00 (9.59–49.41) | 77.78 (51.92–92.63) | 55.56 (22.65–84.66) | 48.28 (29.89–67.10) |
| LDH | 0.572 (0.450–0.695) | 62.92 (56/89) | 18.42 (8.32–34.89) | 44.09 (85.41–99.32) | 77.78 (40.19–96.05) | 61.25 (49.67–71.74) | 0.436 (0.251–0.622) | 42.11 (16/38) | 15.00 (3.96–38.86) | 72.22 (46.41–89.29) | 37.50 (10.24–74.11) | 43.33 (25.98–62.34) |
| DL signaturea | 0.995 (0.987–1.000) | 95.51 (85/89) | 92.11 (77.52–97.94) | 98.04 (88.21–99.90) | 97.22 (83.80–99.85) | 94.34 (83.37–98.53) | 0.950 (0.886–1.000) | 92.11 (35/38) | 95.00 (73.06–99.74) | 88.89 (63.93–98.05) | 90.48 (68.17–98.33) | 94.12 (69.24–99.69) |
| Clinical modelb | 0.652 (0.534–0.770) | 65.17 (58/89) | 39.47 (24.49–56.55) | 84.31 (70.86–92.52) | 65.22 (42.82–82.81) | 65.15 (52.34–76.19) | 0.504 (0.318–0.690) | 50.00 (19/38) | 40.00 (19.98–63.59) | 61.11 (36.14–81.74) | 53.33 (27.42–77.72) | 47.83 (27.42–68.92) |
| Clinical-DL modelc | 0.996 (0.989–1.000) | 95.51 (85/89) | 97.37 (84.57–99.86) | 94.12 (82.77–98.47) | 92.50 (78.52–98.04) | 97.96 (87.76–99.89) | 0.942 (0.867–1.000) | 86.84 (33/38) | 95.00 (73.06–99.74) | 77.78 (51.92–92.63) | 82.61 (60.45–94.28) | 93.33 (66.03–99.65) |
WDLPS, Well-differentiated liposarcoma; LDH, Lactate dehydrogenase; DL, Deep learning; AUC, Area under the receiver operating characteristic curve; PPV, Positive predictive value; NPV, Negative predictive value
aThe deep learning signature was generated from the best deep learning model considering AUC of the validation cohort on different imaging examinations
bThe clinical model was constructed by significant clinical variable, age at diagnosis and LDH selected by multivariate analysis with p value less than 0.05 in the training cohort
cThe clinical-deep learning model was constructed by significant clinical variables, age at diagnosis and LDH, and the deep learning signature
Fig. 2Feature heatmaps of representative patients on the deep learning ResNet50 algorithm via the Guided Grad-CAM. The original CT and MRI images and their corresponding feature heatmaps were shown from left to right. The red color highlighted the region of interest to classify lipoma and WDLPS. The red color focused on different area for lipomas (A) and WDLPS (B) on CT (Left), T1WI (Middle) and T2FS (Right) MRI images, respectively. CAM, Class activation mapping; CT, Computed tomography; MRI, Magnetic resonance imaging; WDLPS, Well differentiated liposarcoma; T1WI, T1-weighted MRI sequence; T2FS, Fat-saturated T2-weighted MRI sequence
Fig. 3Evaluation of predictive performances for the integrated clinical-deep learning nomogram in classification of lipoma and WDLPS. A Nomogram model combining significant clinical variables, age at diagnosis and serum LDH level, and the deep learning signature. The deep learning signature was generated from the multimodality deep learning-based ResNet50 model with the largest AUC value among all models during external validation. B ROC curves for the predictive performance of the integrated clinical-deep learning nomogram in the training and validation cohorts, respectively. C Precision-recall plots for the predictive performance of the integrated clinical-deep learning nomogram in the training and validation cohorts, respectively. D Curves of the calibration analysis for the integrated clinical-deep learning nomogram in the training and validation cohorts, respectively. E The decision curve analysis for the integrated clinical-deep learning nomogram. WDLPS, Well-differentiated liposarcoma; AUC, Area under the receiver operating characteristic curve; ROC, Receiver operating characteristic